Improving drug development by modifying biomolecules using radical methods
Late-Stage Modification of Biomolecules via Radical-Based Methods
This study is looking at new ways to change small molecules and proteins that are important for making medicines, using special techniques to make these changes more precise and effective, which could help improve drug development and our understanding of how these changes work in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10826558 on NIH RePORTER |
What this research studies
This research focuses on enhancing the modification of small molecules and biomolecules, such as alcohols and peptides, which are important in drug discovery. The approach utilizes radical intermediates to achieve selective and specific modifications, overcoming challenges posed by diverse functional groups in these molecules. By employing a phosphoramidite reagent, the study aims to enable targeted functionalization of hydroxyl groups and explore various chemical transformations. The findings could lead to improved methods for drug development and a better understanding of radical chemistry in biological contexts.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals with conditions that could be treated by new drugs developed through these advanced modification techniques.
Not a fit: Patients who are not seeking new treatments or those with conditions that do not involve biomolecular modifications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective drug development processes, resulting in better treatments for patients.
How similar studies have performed: Other research has shown promise in using radical methods for biomolecule modification, indicating that this approach could yield significant advancements.
Where this research is happening
New York, United States
- New York University — New York, United States (Active)
Researchers
- Principal investigator: Diao, Tianning — New York University
- Study coordinator: Diao, Tianning
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.